mapCrowd
Resource Hub banner - my missing millions

Resource Hub

This resource hub provides important resources and recent publications on HCV treatment access barriers, HCV financing resources, updated WHO guidelines on HCV and other partner and government resources on HCV.

Connecting

Government Organizations

Find out more about government support in your country. Download a list of them here (PDF).

Partner Organizations

We collaborate with organisations that provide information and support within individual countries around the world, as well as those with a global or international reach. You can find a list of them here.

Other online resources

Recommended links to other useful data sources and online resources can be found here.

Publications

Have a Heart, Save My Liver! Where is the Cure Registered?

Eight years since the approval of the breakthrough treatment, sofosbuvir, which effectively cures hepatitis C, new direct-acting antivirals (DAAs) regimens have been approved and a variety of treatment access strategies have been used to increase countries’ access.

The hepCoalition developed a fact sheet, based on crowdsourced hepatitis C data from mapCrowd, a free, public database managed by Treatment Action Group and Médecins du Monde. The fact sheet provides in-country data from 82 countries to further understand where the branded and generic versions of the cure have been registered and to inform advocacy efforts for generating demand that could speed up registration. The fact sheet provides supplemental evidence, using community and in-country data, to further understand the registration gaps for direct-acting antivirals (DAAs). The data highlights the availability and registration of DAAs for community leaders and policy makers to reflect in their national elimination advocacy work.

The Opportunity to Eliminate Hepatitis C through Alternative Financing Mechanism

Viral hepatitis is one of the leading causes of death and disability worldwide. Globally, it is the seventh biggest annual killer. It affects more than 350 million – more than HIV/AIDS, tuberculosis or malaria. Fortunately, Hepatitis C (HCV) is curable thanks to the health technologies which have been developed over the past 10 years and hence, it can be eliminated. The financing gap to roll these out and eliminate HCV globally through prevention, screening, testing and treatment has been estimated at USD 41.5 billion between 2018 and 2030. However, not one major philanthropic funder has committed to the goal of HCV elimination and only a handful of countries, mostly high-income, are on track to achieve the World Health Assembly (WHA) elimination targets.

Have A Heart, Save My Liver! Which Countries Restrict Treatment?

Registration of a medicine in a country does not always translate into access. Key populations and marginalized communities disproportionately affected by HCV face stigma, discrimination, and exclusion, which prevent them from accessing a range of health and non-health related services, including the supports needed to initiate treatment on direct-acting antivirals (DAAs). Treatment rationing occurs through different forms of restrictions: based on liver disease stage, abstinence from alcohol and/or substances, and on who is authorized to prescribe DAAs.

A fact sheet, developed by the hepCoalition, shows the three treatment restrictions implemented in 119 countries around the world based on crowdsourced hepatitis C data from mapCrowd, a free, public database managed by Treatment Action Group and Médecins du Monde.

Op-Ed: Political will needed to end the unnecessary suffering of hepatitis C patients

Drugs with a near-100 per cent cure rate have been available for years. To ensure that these are widely available, political leadership and funding are needed. Read the full text here or download it below.

HCV Market Intelligence Report 2021 and Preliminary HBV Market Insights

CHAI's report provides market intelligence on hepatitis C (HCV) diagnostics and drugs in low- and middle-income countries to help guide elimination of the disease. It also covers preliminary insights into the hepatitis B (HBV) market.

New Guidelines on HIV, Hepatitis and STIs for Key Populations

WHO Publishes New Guidelines on HIV, Hepatitis and STIs for Key Populations, read more about in hepCoalition.